What's in Institut de Recherche pour le Developpement's pipeline?

Institut de Recherche pour le Developpement has 7 drugs in our index: 1 marketed, 0 filed, 4 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Institut de Recherche pour le Developpement's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, London School of Hygiene and Tropical Medicine, Allergan, Bayer, Bayer AG.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/institut-de-recherche-pour-le-developpement.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Institut de Recherche pour le Developpement — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Institut de Recherche pour le Developpement pipeline: 1 marketed, 0 filed, 4 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 4 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Chloroquine profilaxis	Chloroquine profilaxis	marketed	Quinoline antimalarial	Plasmodium heme detoxification pathway; DNA/RNA synthesis	Infectious Disease
sulfadoxine-pyrimethamine / mefloquine	sulfadoxine-pyrimethamine / mefloquine	phase 3	Antimalarial	Plasmodium falciparum	Infectious Diseases
Anti-HBV antiviral prophylaxis	Anti-HBV antiviral prophylaxis	phase 3	Antiviral agent		Infectious Disease / Virology
Gatifloxacin combined regimen	Gatifloxacin combined regimen	phase 3	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV	Infectious Disease
Nevirapine, zidovudine, lamivudine	Nevirapine, zidovudine, lamivudine	phase 3	Antiretroviral combination therapy (NNRTI + NRTIs)	HIV reverse transcriptase	Infectious Disease / Virology

Therapeutic area mix

Infectious Disease · 2
Infectious Disease / Virology · 2
Infectious Diseases · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
London School of Hygiene and Tropical Medicine · 2 shared drug classes
Allergan · 1 shared drug class
Bayer · 1 shared drug class
Bayer AG · 1 shared drug class
Carolina Eyecare Physicians, LLC · 1 shared drug class
Centers for Disease Control and Prevention · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Institut de Recherche pour le Developpement:

Cite this brief

Drug Landscape (2026). Institut de Recherche pour le Developpement — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-de-recherche-pour-le-developpement. Accessed 2026-05-16.